



經濟市場檢閱 19 Sep 2026

免責聲明

本錄像內容並非投資意見，亦不構成任何投資產品之要約、要約招攬或建議。本資料只作為教育用途，它並沒有考慮您的個人需要、投資目標及特定財政狀況。投資附帶風險。雖然本資料內的內容是取自獲相信為正確的資料，但本人均不會對本資料內容之準確性、完整性、適時性、精確性作出任何聲明或保證。但本人及其關聯公司並不負上或承擔任何向任何人士或投資者作出建議的責任，亦不會就任何因為或就有關於使用或倚靠本資料或本資料之任何內容而引起之直接、間接或後果性損失承擔任何責任。本資料並不構成投資意見，亦不應被視為任何買入或賣出之招引。投資附帶風險，應尋求獨立的專業意見。

幣股 BNMR MSTR PURR HOOD

生技股 ABCL ABSI MRNA TEM SMMT

軟體股 BB TEAM

核能股 XE

半導體股 INTC

能源股 PBR

礦股 TSO SS1 MEK FXG



市場焦點

Probabilities

Aggregated

Historical

- Historical
- Downloads
- Prior Hikes

Dot Plot

- Chart
- Table


Tools

- CVOL
- SOFR Watch
- ESTR Watch

MEETING DATE	CONTRACT	EXPIRES	MID PRICE	PRIOR VOLUME	PRIOR OI	EASE	NO CHANGE	HIKE
8 12月 2027	ZQZ7	31 12月 2027	95.4550	53	163	0.6%	4.5%	94.8%

Target Rate Probabilities for 8 12月 2027 Fed Meeting

Current target rate is 375-400



TARGET RATE (BPS)


PROBABILITY(%)

Private Credit Default Metrics Cover Different Samples and Definitions

Provider	Default Rate	Coverage	What Counts as Default	Period
Fitch	6.3%	More than 1,300 credit opinions for pooled assets, and more than 350 private ratings	Uncured payment default or distressed debt exchange ¹	Trailing 12 months to August 2026
Houlihan Lokey	0.8% by outstanding principal; 2.5% by count	80,000 loan valuations since 2017 across thousands of borrowers globally	Technical defaults as well as payment defaults	Q2 2026
KBRA	3.3% by count; 2.4% by debt	2,785 global borrowers with more than \$1.2 trillion of direct lending debt	Payment default, imminent default, or intervention that prevents payment default	End of Q2 2026
Lincoln	1.5%	~450 European loans, measured by weighted debt outstanding	Covenant default or payment holiday	Q2 2026
Pimco	19%	BDC borrowers reported by PitchBook with at least \$100 million of assets	Payment default, non-accrual, cash-to-PIK conversion ² , material maturity extension or debt-for-equity swap	Data as of March 31, 2026
Proskauer	2.51%	716 senior-secured and unitranche loans representing \$195.6 billion in original principal	Payment default, distressed restructuring, bankruptcy, covenant default or certain other material defaults	Q2 2026
S&P	0.84% conventional default rate; 3.93% including selective defaults	About 3,900 unrated borrowers with loans held by middle-market CLOs	Traditional default; broader measure also includes selective defaults and distressed restructurings ³	Q2 2026

Note: This chart is intended to show how metrics differ in general terms. Definitions and sample sizes may be more detailed than they are shown to be here. ¹ Fitch says a default debt exchange must meet two requirements: The lender accepts materially reduced terms (PIK doesn't count if documents already allowed such an option), and Fitch must believe that without the changes, the issuer would have likely defaulted on a payment or entered bankruptcy or similar proceedings. ² PIK optionality present at origination is excluded. ³ For S&P, a traditional default includes a bankruptcy filing or a general payment default across the capital structure; a selective default is one where only one lender class is impacted due to a breach in the terms of payment.

AAll Bearish Sentiment (%): 2021 - 2026






醫療及生物科技

Ticker	Company	MC (\$M)	1D%	1M%	3M%	YTD%	Notes
NTRA	Natera	\$53,245	+1%	+19%	+60%	+61%	AI-enabled diagnostics (cfDNA platform combines molecular biology, bioinformatics & AI)
ILMN	Illumina	\$36,183	-2%	+27%	+48%	+83%	genomic-data infrastructure angle & software/analysis layer (sequencing = core business)
GH	Guardant Health	\$24,072	-2%	+12%	+36%	+76%	AI analytics w/ large genomic/clinical datasets for precision oncology (AI important, but diagnostics = core)
TEM	Tempus AI	\$14,045	-3%	+58%	+53%	+32%	healthcare data, algorithmic diagnostics, clinical decision support, and drug discovery
TWST	Twist Bioscience	\$11,066	+7%	+44%	+91%	+426%	produce synthetic DNA, antibody libraries and discovery datasets that can feed AI models (AI core business tho)
TXG	10x Genomics	\$9,980	-0%	+38%	+120%	+370%	high-dimensional single-cell/spatial biology datasets (life-science tools company)
CAI	Caris Life Sciences	\$8,472	-3%	+43%	+62%	+11%	AI/ML + multi-omics + HPC platform for precision oncology and drug-development applications
GENB	Generate Biomedicines	\$2,200	+0%	+7%	+18%	-	generative/predictive ML models used to design novel protein therapeutics
SDGR	Schrodinger	\$2,171	-4%	+64%	+84%	+62%	computational drug discovery; historically physics-based molecular simulation
RXR	Recursion	\$2,050	+8%	+24%	+19%	-6%	computational/automated drug discovery platform built around massive biological/chemical datasets + cpu models
ABSI	Absci	\$1,656	+4%	+9%	+30%	+177%	generative-AI drug design platform combining AI models, synthetic biology and wet-lab validation
CERT	Certara	\$1,284	-2%	+5%	+52%	-4%	core business = biosimulation/model-informed drug development (AI enhancement, not core product)
Average			+0%	+29%	+56%	+117%	
Median			-1%	+26%	+53%	+62%	
MRNA	Moderna	\$61,498	-3%	+145%	+141%	+422%	
ARKG	ARK Genomic Rev ETF		+0%	+20%	+40%	+78%	
XBI	SPDR S&P Biotech ETF		-1%	-2%	+11%	+29%	
SPY	SPDR S&P500 ETF		+0%	-1%	+2%	+12%	

Biotech

Ticker	Company	Price	%1D	Market Cap	P/S	P/E	Chart YTD	% YTD	Chart 1Y	% 1Y	Δ Highs		RS Rank 1M	20SMA	50SMA	200SMA
	ABSI Absci	\$9.44	+17.29%	\$1.6B	1035.62	n/a		+165.92%		+270.20%		-21.72%		▲	▲	▲
	TEM Tempus AI	\$80.61	+15.29%	\$14.5B	10.14	n/a		+33.88%		-6.76%		-22.73%		▲	▲	▲
	TWST Twist Bioscience	\$158.20	+11.61%	\$10.5B	24.28	n/a		+398.58%		+486.58%		1.78%		▲	▲	▲
	BHVN Biohaven	\$13.36	+11.28%	\$2.0B	n/a	n/a		+17.50%		-9.12%		-78.52%		▼	▼	▲
	BFLY Butterfly Network	\$8.00	+10.27%	\$2.1B	19.02	n/a		+107.25%		+390.80%		-20.40%		▲	▲	▲
	CRSP CRISPR Therapeutics	\$57.23	+9.65%	\$5.5B	413.72	n/a		+8.55%		-3.11%		-37.18%		▲	▲	▲
	ABCL AbCellera	\$12.73	+9.68%	\$4.1B	62.65	n/a		+272.22%		+178.56%		1.19%		▲	▲	▲
	NTLA Intellia Therapeutics	\$12.57	+8.92%	\$1.8B	29.47	n/a		+36.19%		+1.29%		-63.95%		▲	▲	▼
	MRNA Moderna	\$159.11	+8.91%	\$63.2B	28.37	n/a		+433.39%		+536.44%		-9.93%		▲	▲	▲
	CMPS COMPASS Pathways	\$14.98	+8.51%	\$2.1B	n/a	n/a		+114.00%		+197.22%		-5.61%		▲	▲	▲
	TXG 10x Genomics	\$78.26	+7.18%	\$10.2B	16.53	n/a		+379.83%		+508.55%		0.50%		▲	▲	▲
	ALMR Alamar Biosciences	\$31.56	+7.18%	\$2.2B	39.39	n/a		+43.45%		+43.45%		-18.11%		▲	▲	▲
	ILMN Illumina	\$244.71	+6.27%	\$36.8B	8.19	45.23		+86.33%		+142.60%		3.69%		▲	▲	▲
	BLLN BillionToOne	\$110.07	+6.48%	\$5.2B	13.10	197.25		+31.82%		+1.04%		-26.83%		▲	▼	▲
	BRKR Bruker	\$63.76	+5.09%	\$9.7B	2.78	n/a		+35.11%		+98.57%		-32.79%		▲	▲	▲
	NTRA Natera	\$362.28	+5.04%	\$52.3B	19.31	n/a		+58.24%		+106.51%		1.44%		▲	▲	▲
	EDIT Editas Medicine	\$2.84	+4.80%	\$438M	9.33	n/a		+37.86%		+4.41%		-75.47%		▼	▼	▲
	NEO NeoGenomics	\$19.73	+4.12%	\$2.5B	3.31	n/a		+66.08%		+143.28%		-0.15%		▲	▲	▲
	MBX MBX Biosciences	\$64.11	+4.13%	\$3.1B	n/a	n/a		+102.88%		+544.97%		-11.74%		▲	▲	▲
	by Lin @speculator_io												September 17, 2026			



by Lin @speculator_io


September 17, 2026

加密貨幣



BTC: Market Cap vs LTH Cap 365d-MA (On-chain Analysis by CryptoChan)





Bitcoin's recoveries have taken six months to three years

The current drawdown is 11 months old and 35% below the peak. The 6 closed ones took 6 to 39 months to regain the old high.

- Closed drawdown
- Current drawdown
- Trough



A drawdown ends when the price regains its previous all-time high, which is the day a new high prints; the shaded width is therefore the time underwater. Drawdowns shallower than 50% are shaded but not labelled: they close in weeks. One drawdown is still open, so its width is an age, not a duration.

Source: CoinMetrics daily bitcoin price (Data/D1_CoinMetrics.csv), 2010-07-18 to 2026-09-18.




金屬

Mining remains undervalued

The demand for commodities is more broad-based than prior cycles, especially for copper

Monthly price performance
(Index, 31 January 1995 = 100)




Source: Bloomberg, S&P Capital IQ, BMO Capital Markets.

Financial results

18 August 2026

Copper demand and supply, 2001 – 2040
(Mt)


Persistent structural deficit could lead to a shortfall of up to **~10 Mtpa** next decade
'Non-traditional'* demand expected to grow by **~6.5%** p.a. 2020 – 2035



Source: Wood Mackenzie, BHP analysis.

Note: Non-traditional uses include decarbonisation, digitalisation and data centre investment.
Supply range refers to committed primary plus scrap copper and is long-term focused.

BHP



軟股票





下周財報



Monday

Tuesday

Wednesday

Thursday

Friday

Before Open

After Close

Before Open

After Close

Before Open

After Close

Before Open

After Close

Before Open

ABIVAX

ABVX



THOR

THO



KBH

MillerKnoll

MLKN



WORTHINGTON ENTERPRISES

WOR



AZO



AYTU BioScience

AYTU



CBRL



GIS



CTAS



PAYX

STITCH FIX

SFIX



H.B. Fuller

FUL



NEOV

BlackBerry

BB



DRI



SNX



COST



LGCY



SCHL